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Efficient Delivery of Transducing
Polymer Nanoparticles for
Gene-Mediated Induction of
Osteogenesis for Bone Regeneration
Aveen R. Jalal and James E. Dixon*
Regenerative Medicine and Cellular Therapies Division, The University of Nottingham Biodiscovery Institute (BDI), School
of Pharmacy, University of Nottingham, Nottingham, United Kingdom
Developing non-viral gene therapy vectors that both protect and functionally deliver
nucleic acid cargoes will be vital if gene augmentation and editing strategies are to
be effectively combined with advanced regenerative medicine approaches. Currently
such methodologies utilize high concentrations of recombinant growth factors, which
result in toxicity and off-target effects. Herein we demonstrate the use of modified
cell penetrating peptides (CPPs), termed Glycosaminoglycan (GAG)-binding Enhanced
Transduction (GET) peptides with plasmid DNA (pDNA) encapsulated poly (lactic-
co-glycolic acid) PLGA nanoparticles (pDNA-encapsulated PLGA NPs). In order to
encapsulate the pDNA, it was first condensed with a cationic low molecular weight
Poly L-Lysine (PLL) into 30–60 nm NPs followed by encapsulation in PLGA NPs
by double emulsion; yielding encapsulation efficiencies (EE) of ∼30%. PLGA NPs
complexed with GET peptides show enhanced intracellular delivery (up to sevenfold) and
transfection efficiencies (up to five orders of magnitude). Moreover, the pDNA cargo has
enhanced protection from nucleases (such as DNase I) promoting their translatability.
As an example, we show these NPs efficiently deliver pBMP2 which can promote
osteogenic differentiation in vitro. Gene delivery to human Mesenchymal Stromal Cells
(hMSCs) inducing their osteogenic programming was confirmed by Alizarin red calcium
staining and bone lineage specific gene expression (Q RT-PCR). By combining simplistic
and FDA-approved PLGA polymer nanotechnology with the GET delivery system,
therapeutic non-viral vectors could have significant impact in future cellular therapy and
regenerative medicine applications.
Keywords: GET, CPP, PLGA NPs, gene delivery, bone regeneration, MSCs, pDNA
INTRODUCTION
Mesenchymal stromal cells (MSCs) are the most employed precursor cell lineage for advanced
bone tissue regenerative strategies. Studies which use biomaterials along with exogenous MSCs or
those that rely on their endogenous populations have shown significantly enhanced bone formation
in critical-size defects when exogenous growth factors (GFs) are applied (Baylink et al., 1993;
Kolambkar et al., 2011; Raftery et al., 2019). Numerous GFs have been identified as bone inducer
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molecules, amongst them bone morphogenetic proteins (BMPs)
are the most widely employed GF family with BMP2 and BMP7
being the most prolifically applied FDA approved GFs used
clinically for orthopedics (Urist, 1965; Lee, 1997; Groeneveld and
Burger, 2000). Bone tissue regeneration through the delivery of
recombinant human (rh)BMP2 such as commercially available
INFUSE R© Bone Graft is a well-established method for spinal
fusion and off-label applications, however protein instability
(with degradation soon after administration) (Shields et al.,
2006; James et al., 2016) means there is a need to apply supra-
physiological concentrations to maintain efficacy within the
therapeutic window, leading to safety concerns. These high
levels of BMP2 are associated with serious side effects such as
ectopic bone formation, osteolysis, aberrant immune responses
and neurotoxicity (Lewandrowski et al., 2007; Tannoury and An,
2014). Therefore, there is a need to develop novel strategies to
apply the activity of BMP2 more safely, physiologically and cost-
effectively to promote bone healing in challenging and critical-
sized bone traumas.
Triggering MSCs to produce BMP2 at more physiological
levels, either from their own genome or via delivered exogenous
transgenes is an alternative approach which does not rely
on recombinant proteins. This can be achieved through
upregulation of the bone differentiation gene regulatory network
by transcription factors (Thiagarajan et al., 2017) or by direct
gene delivery to express new BMP2 copies. In this case, the lower
level of produced protein from transfected cells (picograms-
nanograms) (Raftery et al., 2019) is more physiologically relevant
than current approaches such as application of rhBMP2 (using
milligrams per application). These lower levels result in minimal
or no off-target effects when applied in vivo (Raftery et al., 2019).
Nevertheless, the amount of published work in this field, using
non-viral gene delivery for orthopedic regenerative medicine
is limited mainly because MSCs are difficult to transfect cells
and gene delivery is not easily translated especially in vivo
(Lutz et al., 2008; Lee et al., 2010; Wegman et al., 2011; Park
et al., 2019). Viral gene delivery methods are efficient but
are expensive, are limited in insert size, can be insertionally
mutagenic and sometimes are immunogenic which restricts
their use (Zheng et al., 2000). Most non-viral gene delivery
systems however are not effective in delivering the levels and
efficiency of transfection that are required for therapeutic effect
(Yin et al., 2014). Viral systems have evolved to effectively
navigate the internal cellular barriers to gene delivery, however
endosomal escape of the cargo with non-viral systems is a
further inhibitory facet preventing effective use (Grigsby and
Leong, 2010; Fihurka et al., 2018). Moreover, simplistic non-
viral formulations using cationic molecules with nucleic acids
(such as plasmid DNA; pDNA) which electrostatically form
delivery nanoparticles (NPs) do not protect nucleic acid cargoes
from enzymatic degradation by nucleases (Yang, 2011; Mathur
and Medintz, 2019). It is widely known that polymers used
to produce ‘hard’ NPs such as poly (lactic-co-glycolic acid)
(PLGA) can protect encapsulated nucleic acids from nuclease-
mediated degradation (such as by DNases) (Hirosue et al.,
2001; Abbas et al., 2008). Moreover, the use of PLGA polymers
can improve other aspects of non-viral gene delivery such as
promoting physical stability and prolonged storage for industrial
scalability and pharmaceutical level production (Kapoor et al.,
2015; Sharma et al., 2016).
Glycosaminoglycan-binding Enhanced Transduction (GET)
peptides (Dixon et al., 2016; Eltaher et al., 2016; Abu-Awwad
et al., 2017; Thiagarajan et al., 2017; Osman et al., 2018;
Markides et al., 2019; Raftery et al., 2019; Spiliotopoulos
et al., 2019) are delivery peptides that enhance transduction
and endosomal escape of cargoes in cells. They contain
Heparan Sulfate (HS) binding motifs that enhance binding
to cell surface glycosaminoglycans (GAGs) which concentrate
the cargo on cell membranes, combined with cell penetrating
peptide (CPP) and endosomal escaping peptide elements to
mediate uptake and escape, respectively. We have previously
published the enhanced delivery characteristics and versatile
use of GET peptides, with sequences termed PR (P218R), PLR
(P21LK158R), and FLR (FGF2BLK158R). These sequences can
be used as synthesized L-amino acid peptides or recombinant
protein fusions to deliver red fluorescent protein (mRFP),
pDNA, mRNA, siRNA (Dixon et al., 2016), and magnetic NPs
(Markides et al., 2019). Importantly we have shown GET’s utility
in regenerative medicine by delivering transcription factors
RUNX2 and MYOD for osteogenesis and zonal myogenesis in
three−dimensional gradients (Eltaher et al., 2016; Thiagarajan
et al., 2017), respectively. Moreover, GET peptides have been
used to enhance the delivery and transfection of nucleic acids
for lung gene therapy and bone regeneration in vivo (Osman
et al., 2018; Raftery et al., 2019). The later delivering GF genes
to enhance the repair of a critical size calvarial bone defect in rats
(Raftery et al., 2019).
Here in, we aimed to encapsulate pDNA in a PLGA NP
core to promote enzymatic protection and enhanced physical
stability, and then deliver these to cells by complexation with
GET peptides on the surface for superior delivery efficiency.
Initially, we applied this system to deliver and transfect secreted
reporter gaussia luciferase (gluc)-expressing pDNA as a proof of
concept, we then tested applicability in osteogenesis and using
MSCs in vitro by encapsulation and delivery of BMP2 expressing
pDNA (pBMP2). We demonstrate that the combination of GET
peptide transfection agents, with the pharmaceutical properties
of PLGA NPs can be highly effective for gene therapy, can
help protect nucleic acid cargoes, and is a significant step in
developing future gene augmentation and editing strategies for
use in regenerative medicine.
MATERIALS AND METHODS
Plasmid Preparation
For luciferase assays, reporter plasmid (pDNA) expressing
gaussia luciferase (gluc) was acquired from New England
Biolabs (pGluc). For osteogenic differentiation assays, human
BMP2 expressing pDNA (pBMP2) was a kind gift from
Royal College of Surgeons in Ireland (RCSI) and that used
in Raftery et al. (2019). Both plasmids are driven by an
enhanced cytomegalovirus (CMV) promoter. The plasmids were
transformed in DH5α competent E. coli cells and purified
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by Maxi-prep kits (Qiagen, United Kingdom) as previously
(Raftery et al., 2019).
Condensation of pDNA With PLL
The pGluc vector (5764 bp) or pBMP2 vector (3486 bp)
(100 µg) was complexed with 500 µg of Poly L-Lysine
hydrobromide (PLL) (1000–5000 Da, Sigma, United Kingdom)
by sequentially adding 10 µg of pDNA dropwise to 50 µg of
PLL using a P200 pipette tip under vortexing. The working
concentration was 40 and 200 µg/ml in nuclease-free water
for pDNA and PLL, respectively. The mixture of pDNA-PLL
NPs in a volume of 5 ml was then concentrated to 250 µl
using Amicon R© Ultra Centrifugal Filter units. This volume
of the mixture of pDNA-PLL NPs was encapsulated in the
PLGA NPs by double emulsion as below. The hydrodynamic
size and surface charge of pDNA-PLL NPs were assessed by
Malvern Zetasizer Nano ZS. NP morphology was determined
by Transmission Electron Microscopy (FEI Tecnai BioTwin-12
TEM) as previously (Osman et al., 2018).
Preparation of pGluc and pBMP2
Encapsulated PLGA NPs
Double emulsion (W1/O/W2) was applied to encapsulate pDNA-
PLL NPs (W1) into PLGA NPs. 10 mg of PLGA (with terminal
carboxyl group, PLGA, 50:50, Mw 52000Da, Rosemer Evonic)
dissolved in Dichloromethane (DCM) at concentration of 1.3%
(w/v) was used as the oil phase (O). An aqueous solution
of 0.5% (w/v) Bovine Serum Albumin (BSA) was applied as
the inner phase surfactant. The aqueous phase (pDNA-PLL
NPs + BSA solution) was sonicated in the oil phase for 20 s at
70% amplitude and 70% time on cycle on ice. This emulsion was
immediately poured into a 3% PVA (w/v) (86–89% hydrolyzed,
medium molecular weight, Alfa Aesar) aqueous solution (W2)
and sonicated again at the same rate. After evaporation of
DCM, the pDNA-encapsulated PLGA NPs were collected by
centrifugation at 20,000 g for 20 min at 4◦C and washed
twice with deionized water to remove excess PVA and unbound
pDNA. The NPs were re-suspended in 500 µl of 1.6% (w/v)
Trehalose solution in a ratio of 1:1.5 by weight, respectively, then
freeze dried and stored at −20◦C until further use. To prepare
fluorescently labeled PLGA NPs, hydrophilic and hydrophobic
fluorescent dyes: Atto590 or Nile Red (1 mg) was encapsulated
instead of pDNA-PLL NPs.
Measurement of EE%
To measure the encapsulation efficiency percentage (EE%),
5.5 mg of pDNA encapsulated PLGA NPs were dissolved in
1 ml DCM. 1 ml of 1x TE buffer (Tris-EDTA, Thermo Fisher
Scientific) aqueous solution was added to the dissolved PLGA
NPs to extract the encapsulated pDNA. The immiscible
mixture of DCM/aqueous layer was separated by brief
centrifugation. The aqueous layer was then transferred and
the EE% was measured by PicoGreen in which the amount
of pDNA detected form the solubilized PLGA NPs was
subtracted from the total amount of pDNA used. A pDNA-
PLL NP solution was used to construct a standard curve
(Gebrekidan et al., 2000; Ribeiro et al., 2005). The amount of
pDNA-PLL was calculated using Quant-iT PicoGreen dsDNA
Assay Kit (Life Technologies).
pDNA Integrity and DNase Protection
Assay
To determine the effect of sonication on supercoiling and
integrity of pDNA, sonicated and non-sonicated pDNA and
pDNA-PLL NPs (as controls) and pDNA-PLL extracted from
PLGA NPs was quantified and transformed into competent
DH5α E. coli, with the number of bacterial colonies were
compared as a quality measure. Moreover, to confirm the pDNA
protection ability of PLGA NPs, 0.5 µg of naked or encapsulated
pDNA was incubated with increasing concentrations of DNase
I at 37◦C for 15 min. DNase I was prepared by diluting DNase
I stock solution of 2.72 U/µl to 0.025 U/µl, 0.0025 U/µl and
0.00025 U/µl in DNase buffer according to the manufacturer’s
instruction (RNase-Free DNase kit, Qiagen). The buffer was
2.5 mM Magnesium chloride and 1 mM Calcium chloride in
PBS. The digestion reaction was stopped by adding EDTA at
0.5M final concentration. Naked pDNA and pDNA-encapsulated
PLGA NPs were run on 1% (w/v) agarose gel in 1x TAE buffer
with Ethidium bromide (EtBr) and imaged on a Luminescence
Image Analyser (LAS-4000, Fuji).
GET Complexation With PLGA NPs
Blank, fluorescent dye- (Atto590 or Nile Red) or pDNA-
encapsulated freeze-dried PLGA NPs were resuspended in PBS
and complexed with GET peptide at different concentrations.
The mixture was left to electrostatically interact for 15 min
at room temperature. The complexation was confirmed by
a shift in the surface charge of PLGA NPs measured by
Zetasizer Nano ZS as previously described (Osman et al.,
2018). This procedure was applied to produce PLGA-GET
complexes for enhanced delivery and transfection, as well as
differentiation studies.
To assess enhanced delivery with PR, PLR, or FLR peptides,
fluorescent dye-encapsulated PLGA NPs were used. This mixture
of PLGA-GET was added to pre-seeded, washed NIH3T3 or
IHMSCs (Immortalized human Mesenchymal Stromal Cells)
(Thiagarajan et al., 2017) in a total volume of 250 µl of
growth media (GM; 10% fetal calf serum; FCS) or serum
free media (SFM).
Assessment of Enhanced Intracellular
Delivery With PLGA-GET Complex
To demonstrate the enhanced delivery of PLGA NPs
intracellularly, hydrophilic dye Atto590 and hydrophobic
dye Nile Red encapsulated PLGA-GET NPs were delivered
to NIH3T3 or IHMSCs cells. The complex was incubated
overnight with the cells in either GM or SFM. The following
day, transduced cells were washed twice with PBS and imaged by
fluorescent microscopy (Leica DM IRB) using a green laser before
being processed for flow cytometry. For flow cytometry, cells
were trypsinized with trypsin/EDTA [0.25% (w/v) trypsin/2 mM
EDTA] and fixed with 4% (w/v) paraformaldehyde (PFA).
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 3 August 2020 | Volume 8 | Article 849
fbioe-08-00849 August 3, 2020 Time: 12:4 # 4
Jalal and Dixon PLGA-Peptide Non-viral Gene Delivery
PLGA-GET cellular internalization was quantified using a
Beckman Astrios Cell Sorter and 590 nm laser (20,000 cells, gated
on untreated cells by forward/side scatter). Mean fluorescence
intensity was used for statistical analysis.
Assessment of Enhanced Transfection
With PLGA-GET Complex
To assess enhanced transfection, pGluc (gluc encoded pDNA)-
encapsulated PLGA NPs were complexed with variants of GET
peptides; PR, PLR or FLR. These NPs were incubated with
NIH3T3 cells overnight. Luciferase signal was measured the next
day by luminometer and compared with controls (as previously
described) (Raftery et al., 2019). Dose of GET peptide per mg
of PLGA NPs was optimized based on transduction efficiency,
transfection levels and cell viability studies.
Cell Culture
Cells were cultured as described previously and incubated at
37◦C and 5% CO2 (Skarn et al., 2014; Thiagarajan et al., 2017;
Osman et al., 2018). Both NIH3T3 and IHMSCs (TERT and E6/7
immortalized in-house) were used for transduction, transfection
and viability assessments of PLGA-GET NPs. IHMSCs were
specifically used to deliver pBMP2-PLL encapsulated PLGA
NPs and pBMP2-FLR for osteogenic differentiation assays as
comparators. The IHMSCs were maintained in expansion media;
Dulbecco’s modified Eagle medium (DMEM) supplemented with
20% (v/v) FCS, 2 mM L-glutamine, 100 units/ml penicillin, and
100 mg/ml streptomycin and 1% (v/v) Antibiotic/Antimycotic.
The cells were passaged at 80% confluency and used at
passages below 20. For intracellular delivery, transfection and
differentiation studies, NIH3T3 and IHMSCs were seeded at
a density of 100K and 35K per well in 24-well plate culture
dishes, respectively. The cells were then incubated overnight to
allow attachment. Before delivery of NPs, media was replaced,
and the cells were washed twice with PBS. Two hundred
microliter of GM or SFM media was added then completed
with 50 µl transfection media. The transfection media was
left for 3 days and media then replaced with 500 µl of the
relevant media.
Metabolic Activity Assays
Metabolic activity of IHMSCs were detected after transfection
with pDNA encapsulated PLGA-GET NPs using PrestoBlue
assay. Two hundred microliters of 10% (v/v) of the reagent in
HBSS (Hanks’ Balanced Salt solution, Thermo Fisher Scientific)
was added to 24-well plate. Prior to the addition of the
reagent, the old media was removed, and the cells were washed
with PBS trice. The reagent was left for 20–25 min and the
fluorescence was measured on a plate reader (Infinite PRO,
TECAN) at 560/590 nm.
Osteogenic Differentiation Assays
The osteogenic assays were first optimized and adapted
for FLR transfection. pBMP2-FLR NPs were generated by
mixing pBMP2 with FLR at a charge ratio (±) of 6 and
a peptide final concentration of 2 µM in serum reduced
media (OptiMEM, Life technologies) as described previously
(Raftery et al., 2019). IHMSCs were seeded, incubated
overnight and transfected with 0.5 µg pBMP2-FLR NPs.
DMEM/F12 Ham 1:1 (Life Technologies, United Kingdom)
supplemented with 10% (v/v) FCS, 2 mM L-glutamine, 100
units/ml penicillin, and 100 mg/ml streptomycin, 50 µg/ml
L-ascorbic acid 2-phosphate sesquimagnesium salt hydrate
(Sigma, United Kingdom) and 10 mM b-glycerophosphate
disodium salt pentahydrate (Acros Organics, United Kingdom)
was used as basal media (BM). Osteopermissive (OP) and
Osteoinductive (OI) media contained low (10 nM) and
high (100 nM) Dexamethasone (Dex) in BM, respectively
(Thiagarajan et al., 2017). These media combinations were used
to test the effectiveness for pBMP2 delivery to induce osteogenic
differentiation. For osteogenic differentiation with pBMP2-
encapsulated PLGA NPs, 200 µg of PLGA NPs equivalent
to 1 µg of encapsulated pBMP2 content was complexed
with FLR at a final concentration of 4 µM FLR. In both
cases of pBMP2-FLR and pBMP2-encapsulated PLGA-FLR
NPs, the cells were delivered with a single transfection in
OP media.
Alizarin Red Staining
At week three, cells were analyzed microscopically for
extracellular matrix and bone nodule formation. At week
four, the osteogenic cultures were stained for calcium deposition
using 2% (w/v) Alizarin Red solution (Alfa Aesar). To do
this, cultures were washed three times with PBS and fixed
with 4% (w/v) PFA followed by the removal of PFA and
washing with deionized water three times. The cultures were
stained for 5 min using 200 µl Alizarin Red solution. The
excess Alizarin Red solution was removed and the cultures
were washed with deionized water. This was followed by
incubation in deionized water for 2 h to remove the background
staining. For calcium quantification, the stained cultures were
washed three times with deionized water and Alizarin Red
was extracted by the addition of 200 µl 10% (v/v) acetic
acid (Sigma) for 30 min while shaking. The eluted stain
was transferred to microfuge tubes and heated at 85◦C for
10 min, cooled and neutralized with 10% (w/v) ammonium
hydroxide (Sigma). The absorbance was read at 405nm on a
plate reader (Infinite PRO, TECAN) (Gregory et al., 2004).
Fold increase in molar concentration was compared to controls
maintained in expansion media, basal media, OP or OI media
(Gregory et al., 2004).
Gene Expression Analysis
Quantitative reverse transcription polymerase chain
reaction (Q RT-PCR) was used to detect the level of
osteogenic gene upregulation. Total RNA was extracted
from differentiated IHMSCs using RNeasy kits (Qiagen).
On column DNase I treatment was applied using
RNase-free DNase kits (Qiagen). 0.4 µg total RNA was
reverse transcribed in 20 µl reaction using SuperScript
III Reverse Transcriptase (Life technologies) according
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to manufacturer’s protocol. Q RT-PCR reactions were
performed using Taqman assays (Applied Biosystems, Life
technologies). Osteogenic genes (ALP–Hs01029144_m1;
RUNX2–Hs00231692_m; BGLAP–Hs01587814_g1;
SPP1–Hs00959010_m1) were detected against B-actin
(ACTB-Hs99999903-m1) reference gene. Relative expression
level was calculated using 11CT method. Five biological
replicates with three technical replicates were performed
for each treatment.
Statistical Analysis
Statistical analysis and graphs were generated using GraphPad
Prism software package. Unpaired t-test and One-way Anova
were used to determine significant variances between two
groups or more respectively. Two-way Anova was used for
grouped data. One-way and two-way Anova was followed
by Tukey test to determine significance between each
mean in multiple comparison. The data represented as
mean ± SD. Variances between means were considered
statistically significant with p-values: 0.0332 (∗), 0.0021 (∗∗),
0.0002 (∗∗∗), and <0.0001 (∗∗∗∗). Experimental numbers
were a minimum of five biological replicates, with three
technical replicates for all data except NP characterization
which were minimum of three biological replicates and three
technical replicates.
RESULTS
Characterization of pDNA-PLL NPs
For macromolecular hydrophilic and negatively charged plasmid
DNA (∼7 megaDa) to be encapsulated into hydrophobic and
relatively small 350 nm PLGA NPs, it is necessary for the pDNA
to be condensed into a smaller size in proportion to the final
PLGA NPs. We also aimed for pDNA to be converted to a
more water insoluble and positively charged form to allow for
more effective encapsulation. To do so, we used low molecular
weight PLL (1–5 kDa) that is efficient in condensing large
pDNA molecules. It is accepted that low molecular weight
polycations can condense pDNA at charge ratio (±) equal or
higher than 1. In this study, we have condensed pGluc and
pBMP2 at weight ratio of 5 and charge ratio of 12 (PLL/pDNA) to
produce small 30–60 nm (Figures 1A,C) and positively charged
pDNA-PLL NPs (Figure 1B). These NPs are relatively uniformly
distributed with an average Poly Dispersity Index (PDI) of
0.1± 0.03 (mean± SD) (Wolfert and Seymour, 1996). Moreover,
these NPs are spherical in morphology as showed on TEM
images (Figure 1C).
Encapsulation and Characteristics of
pDNA-Encapsulated PLGA NPs
Both pGluc- and pBMP2-PLL NPs were encapsulated in
PLGA NPs using a double emulsion method (Figure 2A).
This process yielded a minimum encapsulation efficiency (EE)
percentage of ∼30% of the initial pDNA used. Blank PLGA
NPs control were prepared by substituting the pDNA-PLL with
water only. Blank PLGA NPs and pDNA-PLL NPs passed
through the same double emulsion method but without the
PLGA, were used as controls for measuring EE% and within
transfection assays. The blank and encapsulated PLGA NPs
are in the range of 350 nm in diameter with average PDI
of 0.17 ± 0.02 (mean ± SD) shown by Zetasizer and TEM
analyses (Figures 2B,C, respectively) with a negative surface
charge (Figure 2D).
It was imperative to evaluate the possibility of unfavorable
surface attachment of positively charged pDNA-PLL NPs on
the negatively charged PLGA NPs by electrostatic interaction
during the process of double emulsion. This effect might result
in surface bound pDNA on PLGA NPs and consequently
transfection as a result of binding rather than encapsulation
of pDNA. To determine this, we considered and assessed
many checkpoints during the formulation methodology. First,
we compared the surface charge of pDNA-encapsulated PLGA
NPs with blank NPs (Figure 2D); the charge of both NPs is
negative which indicates no or little attachment of positively
charged pDNA-PLL on the surface of PLGA NPs. Secondly,
FIGURE 1 | Characteristics of pDNA-PLL NPs. (A) NP size measured with Zetasizer Nano shows relatively small and homogenous distribution of NPs. (B) An image
of a Zeta potential report indicates positive surface charge of NPs. The NPs were prepared and measured in nuclease free water; the same condition used for
encapsulation in the double emulsion process. (C) TEM images demonstrate size and morphology of the same NPs. Red arrows highlight individual NPs.
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FIGURE 2 | Characterization of pDNA-encapsulated PLGA NPs. (A) A simplified illustration of the process of pDNA encapsulated PLGA NP preparation and GET
peptide complexation. (B) Representative PLGA NP size for both blank and pDNA encapsulated, shows homogenous population of the NPs measured by Zetasizer.
(C) TEM micrograph of these NPs which confirms the size measured by Zetasizer and demonstrates the spherical, smooth surface of the NPs. Red arrow highlights
individual NP. (D) The negative surface charge of pDNA-encapsulated PLGA NPs is comparable to blank NPs and excludes the possibility of PLGA NPs surface
contamination with positively charged pDNA-PLL NPs. (E,F) Demonstrates the integrity of the encapsulated pDNA during the preparation process or the enzymatic
treatment with DNase I respectively. Doses of DNase I tested were: 0.025, 0.0025, and 0.00025 U/µl with 15 min incubation time at 37◦C.
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to control for the sedimentation of pDNA-PLL NPs during
centrifugation and contribution to transfection, pDNA-PLL
NPs were passed through the same process without PLGA
(i.e., double emulsion, centrifugation and washing steps). No
pellet of pDNA-PLL was found by centrifugation and we used
these samples as controls in both measurements of the EE%
and transfection of cells. As a result, no pDNA was detected
in the supernatant. Additionally, even when complexed with
GET peptides this did not result in significant detectable
transfection in NIH3T3 cells. These controls confirm that
pDNA-PLL NPs do not attach significantly to the surface of
PLGA NPs and therefore hypothesized that almost all the
pDNA is encapsulated within the PLGA NPs. We hypothesize
that if pDNA is not encapsulated it does not sediment by
centrifugation and is lost during the washing steps in the double
emulsion process.
We next assessed the exposure of pDNA to the external
microenvironment as a function of its encapsulation efficiency
(Figures 2E,F). We confirmed that the encapsulated pDNA
in PLGA NPs is prevented from migration through the
gel and the PLGA protects the encapsulated pDNA from
enzymatic treatment with DNase I, even at the highest doses
which would be beyond anything physiological (Figure 2F).
Moreover, there is a minimal effect of sonication on the
integrity of pDNA at the rates used to prepare these NPs;
this was confirmed by pDNA extraction and bacterial
transformation assays demonstrating intact pDNA against
sonicated and non-sonicated pDNA and pDNA-PLL NPs
controls (Figure 2E).
PLGA-GET NP Characteristics for
Enhanced Intracellular Delivery
Upon complexation of negatively charged blank or pDNA-
encapsulated PLGA NPs with positively charged GET peptides,
the surface charge significantly changes from negative to a
neutral or slightly positive charge (Figure 3A). We tested several
variants of GET peptides namely P218R (PR), P21LK158R
(PLR), and FGF2BLK158R (FLR); all three variants of GET
peptide enhance the delivery of PLGA NPs to cells. However,
the most significant enhancement in delivery as assessed by
flow cytometry was observed when NPs were coated with
LK15-containing peptides (i.e., PLR and FLR) over those
lacking it (i.e., PR), or those with the FGF2B HS binding
motif (over P21), and in general delivery was higher in SFM
than in GM (Figure 3B). This was also confirmed with
fluorescence microscopy (Figure 3C). We hypothesize this may
be due to stronger electrostatic interaction within PLGA-GET
complexes in SFM. The zeta potential change of PLGA-GET
complexes incubated with increasing concentration of serum
could potentially explain this (Supplementary Figure S1). Upon
incubation for 15 min, PLGA-GET NP surface charge becomes
more negatively charged with serum reaching approximately
−10 mv in 10% FCS containing GM media. This effect is
likely due to the binding of negatively charged serum proteins
such as albumin with positively charged GET peptides on the
surface; or that serum induces minimal dissociation of GET
peptides from the NPs exposing some of the negatively charged
PLGA NP surface.
Optimizing the GET Peptide NP Coating
for Efficient Cell Transfection
pGluc-encapsulated PLGA NPs were used to assess transfection
efficiency with GET peptide complexation. PR has been
previously used to deliver many cargoes such as mRFP
recombinant protein, magnetic NPs (Dixon et al., 2016; Markides
et al., 2019), recombinant runt-related transcription factor
RUNX2 (Thiagarajan et al., 2017) and MYOD for zonal
myogenesis (Eltaher et al., 2016). However, when employed
in the delivery of nucleic acids, PR is not sufficient to
produce significant levels of transfection even with enhanced
delivery characteristics. This is likely to be due to PR lacking
LK15 which is the endosomal escape activity of the system
(Saleh et al., 2010; Alkotaji et al., 2014; Ahmed, 2017)
(Figure 4A). Corroborating experiments using fluorescent pDNA
complexed with PR compared to PLR and transfected into
NIH3T3 produced almost the same NPs in terms of physico-
chemical characteristics and cellular internalization levels (by
fluorescent microscopy and flow cytometry analysis) but
only PLR showed effective transfection levels by luciferase
assaying (Supplementary Figure S2). Additionally, it appears
that fluorescent NPs are more diffusely localized in cytosol
with PLR delivery and potentially accumulated more in the
endosomes for PR (Supplementary Figure S2). Conclusively,
the presence of LK15 is essential for pDNA-encapsulated PLGA
NPs transfection. Therefore, GET peptides which bear LK15, i.e.,
PLR or FLR were utilized for transfection studies (Figure 4).
When transfecting NIH3T3, complexation of PLR or FLR with
PLGA NPs significantly increases the level of transfection by up
to five orders of magnitude, in comparison to non-complexed
PLGA NPs (Figure 4A). It is noteworthy that although there
is some low degree of internalization of non-complexed PLGA
NPs, this does not result in any levels of detectable transfection
above background (102 RLU). Moreover, SFM produced slightly
higher transfection levels over GM conditions, which aligns
with the enhanced transduction characteristics seen in the
same media (Figure 4B). As we aimed to demonstrate the
utility of our PLGA-GET system in biomedical applications,
with a focus on osteogenic differentiation and regenerative
medicine, we optimized the dose of both PLR and FLR
peptide coating per weight of PLGA NPs for transfection
studies of immortalized human Mesenchymal Stromal Cells
(IHMSCs). The optimized dose was chosen based on levels of
internalization (Figures 4C,D, for PLR and FLR respectively),
and as FLR was superior this was taken forward for transfection
(Figure 4E) and cell viability assays (Figure 4F). We found
that with increasing FLR peptide, the transfection levels
improved until reaching saturation at 4 µM (Figure 4E).
There was slightly reduced cell viability in highly susceptible
cell line such as IHMSCs at very high concentrations of
FLR > 20 µM (for 0.2 mg PLGA NPs) especially in SFM
(Figure 4F), which is also the case for other transfection systems
(Jeong and Park, 2002).
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FIGURE 3 | Enhanced delivery of PLGA NPs with GET peptides. (A) Interaction between GET peptides and PLGA NPs (Blank and pDNA-encapsulated) and
confirmation of PLGA-GET complex formation through a shift in the surface charge of PLGA NPs measured by Zetasizer. (B) All variants of GET peptides enhance
the delivery of PLGA NPs significantly in comparison to non-complexed PLGA NPs. PLGA-FLR NPs are associated with the highest levels of uptake followed by
PLGA-PLR NPs quantified by flow cytometry analysis. (C) Fluorescence microscopy images of NIH3T3 cells after addition of Nile Red-, Atto590-encapsulated PLGA
NPs with and without GET peptide complexation in 10% FCS containing media (Growth media, GM) or SFM. The peptide significantly enhances the PLGA NPs,
especially in SFM. Scale bar 100 µm. The asterisk over the bars indicate significance to control (PLGA NPs), the asterisk over the lines indicate significance between
groups. One-way and two-way Anova statistical analysis was used to generate the graph followed by Tukey test to determine significant differences between each
mean. The data represented as mean ± SD. P-value were < 0.0001.
Based on these assays, the optimized dose of 4 µM FLR (per
0.2 mg NPs) was employed for validating our systems use in
differentiation studies. Interestingly, FLR-pDNA complexes have
previously been shown as superior to PLR in transfecting hard
to transduce cells (such as MSCs) when using smaller doses of
pDNA (Osman et al., 2018). Importantly these studies confirm
this also the case for PLGA NP formulations.
Osteogenic Differentiation Assays
To determine efficacy of non-PLGA encapsulated pBMP2-
FLR NPs in osteogenic differentiation (Figure 5A for
assay), we confirmed that the previously published GET
peptides alone can induce osteogenesis in IHMSCs with
exogenous transgene-mediated BMP2 expression (Figure 5B
middle section) (Supplementary Figure S3 for physico-
chemical characterization) (Osman et al., 2018). Single
transfection was used in osteopermissive (OP) media and a
minimum dose of 0.5 µg of pBMP2-FLR transfection mix
was required to induce osteogenesis. Next we compared the
efficacy of pBMP2-PLGA-FLR and pBMP2-FLR NPs in this
assay differentiation was confirmed for both systems. IHMSCs
initially changed morphology from fibroblastic to polygonal
shaped cells in the early stages of differentiation (week 1),
followed by increased deposition of ECM and calcium nodules
forming on cells observed by light microscopy starting from
week 3 (Figure 5B pre-stain). This differentiation was also
confirmed by Alizarin Red staining at week 4 (Figure 5B).
Extracted Alizarin Red from stained wells was used as a
relative quantification method of the calcium nodule numbers
confirming that both published GET NPs (Raftery et al., 2019)
and the PLGA-GET NPs can induce similar levels of oestogenesis
(Figure 5C). Ten-fold increase in molar concentration of
the absorbed dye by the calcium nodules was demonstrated
for BMP2-transfected cells in comparison to controls in
expansion, basal, OP media and those in OP media transfected
with pGluc-FLR NPs.
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FIGURE 4 | Enhanced transfection of PLGA NPs with GET. (A) Levels of transfection of different GET peptide complexation showing high levels of transfection of
pDNA encapsulated PLGA NPs complexed with PLR and FLR in NIH3T3 cells, Corresponding 1 µg of pDNA content. (B) Validation of the encapsulated pDNA and
the ability to transfect against controls (pDNA-PLL). Dose optimization of PLR (C) and FLR (D) peptides in IHMSCs. Transduction level increases with increasing the
dose of both PLR and FLR. Enhancement reaches saturation at 4 µM FLR peptide. (E) Dose dependent enhanced transfection of IHMSCs, as a result of enhanced
transduction by FLR. In line with transduction levels, with increasing FLR peptide concentration, the transfection levels improve until reaching saturation. (F) Cell
metabolic activities 24-h after transfection with different doses FLR (highest transduction activity) in IHMSCs. In contrast to Lipofectamine 3000, FLR peptide show
high margins of cytocompatibility especially in GM. The asterisk over the bars indicate significance to control (PLGA NPs), the asterisk over the lines indicate
significance between groups. One-way and two-way Anova statistical analysis was used to generate the graph followed by Tukey test to determine significant
differences between each mean. The data represented as mean ± SD. Where significance was ** or ****, P-value was <0.0021, or <0.0001 respectively.
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FIGURE 5 | Osteogenic differentiation as a result of pBMP2 encapsulated PLGA- GET delivery. (A) Phase contrast microscopic images (pre-stain) and Alizarin Red
stained microscopic and whole well images of control IHMSCs in expansion, basal, OP and OI media. (B) Phase contrast microscopic images (pre-stain) and Alizarin
Red stained microscopic and whole well images produced dense calcium deposits in cultures transfected with pBMP2-FLR and pBMP2 encapsulated PLGA NPs in
comparison to controls. Cells were cultured at 35k cells in 24-well plate format. Scale bar 100 µm. (C) Quantification of Alizarin Red stained calcium nodules; (mM)
fold increase in dye absorbed calcium of transfected cultures in comparison to controls. (D) Significant activation of the osteogenic genes: ALP (Alkaline
Phosphatase), RUNX2 (Runt Related Transcription Factor 2), BGLAP (Bone Gamma-Carboxyglutamate Protein) also called Osteocalcin, and SPP1 (Secreted
Phosphoprotein 1) also called Osteopontin at week four from IHMSCs either treated with pBMP2-FLR NPs or pBMP2-encapsulated PLGA-FLR NPs in comparison
to non-transfected cells. The graph was plotted based on expression fold change to cells cultured in expansion media only. One-way and two-way Anova statistical
analysis were used to generate the graphs followed by Tukey test to determine significant differences between each mean. The data represented as mean ± SD.
Where significance was *** or ****, P-value was, 0.0002 or <0.0001 respectively.
Cultures in basal media, Osteopermissive (OP), or transfected
with pGluc instead of pBMP2 resulted in no spontaneous
osteogenic differentiation. Moreover, highly osteoinductive
(OI) media with Dexamethasone produced similar levels
of differentiation as those of pBMP2 transfected samples
(Figure 5A). Furthermore, elevated levels of osteogenic
specific genes in transfected cells with both pBMP2-PLGA-
FLR and pBMP2-FLR were confirmed by Q RT-PCR.
Importantly, late osteogenic marker, matrix synthesis
and mineralization specific gene; BGLAP was significantly
upregulated in the transfected cells over the control in basal
media and OP (Figure 5D) (Lian et al., 1989; Ryoo et al.,
1997; Thiagarajan et al., 2017). Cell viability assays showed
minimal toxicity of pBMP2-encapsulated PLGA-FLR NPs
during the course of transfection in the differentiation studies
(Supplementary Figure S4).
DISCUSSION
Non-viral gene delivery vectors are known for their low efficiency
when compared to viral vectors. Examples of non-viral systems
include cationic polymers which act to both condense and
enhance the delivery of nucleic acids. However, for enhanced
gene delivery characteristics, high doses or highly positively
charged variants are generally employed (Kadlecova et al., 2012;
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Hall et al., 2017). This high positive charge is directly related
to cellular toxicity (Moghimi et al., 2005). Moreover, cationic
agents only partially protect the nucleic acid cargo against
enzymatic degradation (Roy et al., 2003; Hu et al., 2016). On
the other hand, the use of effective versions of bio-inert hard
polymers such as PLGA, would represent a significant step
forward in non-viral gene delivery because of their advantages
in attaining maximum DNase enzymatic protection and low
toxicity (Han et al., 2000; Jin et al., 2014; Chen et al.,
2016). PLGA is a gold standard in developing macromolecule-
encapsulated particles such as for proteins and nucleic acids.
Encapsulation protects the macromolecule from degradation
by enzymes such proteases/nucleases and other environmental
factors such as infected matrices and non-physiological pH
(Pack et al., 2005; Ding and Zhu, 2018). Our demonstration
here provides the foundation for developing future first-in-class
pharmaceutical gene therapy product. However, such PLGA
NPs poorly internalize and yield almost no transfection levels
in vitro or in vivo when adequately removing and controlling
for contaminating nucleic acids left from the fabrication process
(Torchilin, 2008; Steinbach et al., 2016; Kim et al., 2019).
Modifications of CPPs such as GET peptides have improved
nucleic acid delivery and are associated with low cytotoxicity
when compared to competitor transfection agents such as
Polyethylenimine (PEI) and Lipofectamine family agents (Life
Technologies) (Grigsby and Leong, 2010; Kapoor et al., 2015). We
have previously published our pDNA-GET NP system (Osman
et al., 2018; Raftery et al., 2019), in which we demonstrated
superior gene delivery, transfection efficiency and improved cell
viability for lung and bone gene therapy applications. However,
condensation of the plasmid with GET peptides to form a
NP complex is not sufficient to fully protect the encapsulated
pDNA from enzymatic degradation (Abbas et al., 2008; Osman
et al., 2018), especially when applied in vivo. Therefore, in this
work we encapsulated pDNA in the core of the PLGA NPs for
almost total protection against DNases and the GET peptide
system was complexed pDNA-encapsulated PLGA NPs by facile
incubation to efficiently deliver high transfection levels into cell
lines and human MSCs.
For encapsulation of nucleic acids, it is important that the
process is controlled using proper experimental comparisons,
which has been lacking in some previous studies using PLGA
encapsulation (Capan et al., 1999; Tahara et al., 2008, 2010;
Patil and Panyam, 2009; Zhao et al., 2013). There are several
techniques to enhance the encapsulation of macromolecules such
as nucleic acids in PLGA NPs (Mok and Park, 2008; Tahara et al.,
2008; Danhier et al., 2012); one being the use of cationic reagents
to condense and minimize the effective size of the macromolecule
hence attaining higher encapsulation efficiencies. However, in
previous studies the process is poorly controlled and these did
not follow the dynamics of encapsulation and specifically address
where the condensed nucleic acid were located; either being
encapsulated in core or bound to the surface of the PLGA NP.
It is highly likely that the small sized positively charged NPs
(cationic polymer condensed nucleic acids) bind to the surface of
negatively charged PLGA NPs through electrostatic interactions.
The surface binding produces a slightly positive or neutral PLGA
NPs as a result of charge neutralization; an effect identified
by measuring the surface charge in comparison to blank NPs.
In the present work, we have accounted for this possibility;
moreover, we have applied other parameters to ensure that non-
encapsulated DNA-PLL NPs do not sediment with the PLGA NPs
during fabrication by centrifugation. To confirm that transfection
was entirely attributable to encapsulated pDNA, we passed
pDNA-PLL NPs through double emulsion process without the
inclusion of PLGA. This control was used to quantify estimated
pDNA-PLL NPs by DNA quantification and measure its effect on
transfection. Both controls have successfully proven no surface
attachment or sedimentation of DNA-PLL NPs occurred during
the process of PLGA NP preparation and transfection is entirely
due to encapsulated pDNA in the core of PLGA NPs. We believe
our investigation is one of the first studies to take into account
such controls for encapsulation.
Complexation of PLGA NPs with GET peptides significantly
enhances the intracellular delivery and consequently transfection
levels confirmed by reporter gene expression (pGluc). We
employed a human MSC line that can differentiate to bone
lineages given the correct stimulus (here ectopic BMP2
stimulation) to optimize the use of PLGA-GET NPs for
bone regenerative medicine. It is known that BMP2 alone
is not sufficient to induce human MSCs toward bone
differentiation in in vitro conditions (Yang et al., 2003;
Wang et al., 2016; Raftery et al., 2017; Loozen et al., 2018),
and there are species differences between human and
rodent MSCs in ease of specification (Diefenderfer et al.,
2003; Osyczka et al., 2004; Acil et al., 2014). It is therefore
important to culture hMSCs in a permissive but not inductive
environment to test the activity of BMP2 gene delivery to
trigger osteogenesis. We therefore added sub-threshold levels
of Dexamethasone (10 nM) to generate osteopermissive (OP)
conditions and media. It is important to note that native
glucocorticoids are considered essential for initial morphological
fibroblastic to polygonal changes for lineage specification
(Jaiswal et al., 1997). We compared OP conditions to high
Dexamethasone (100 nM) i.e., Osteoinductive (OI) media,
which is capable of inducing differentiation without BMP2
supplementation.
Confirmation of osteogenic differentiation by Alizarin
Red staining, upregulation of osteogenic genes and cell
viability studies suggest that pBMP2 encapsulated PLGA-
GET is an effective gene delivery system in osteogenesis
with no significant cytotoxic effects, and comparative to our
published studies (Osman et al., 2018; Raftery et al., 2019).
We confirm that transfection activity is not due to excessive
positive charge as it is associated with other non–viral gene
delivery vectors. Indeed these PLGA-GET complexes are
neutrally charged and the enhanced transfection is entirely
mediated by the delivery characteristics of GET peptide,
including the requirement for effective endosomal escape
activity. This system has many other advantages compared
to the current non-viral gene delivery vectors, including GET
peptide delivery alone, as it combines the benefits of gene
protection, efficient transfection, and the potential for prolonged
storage and stability. These attributes are significant when
developing and translating a pharmaceutical gene delivery
product. Moreover, our system could be used to encapsulate and
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deliver multiple regulatory factors to harness synergistic effects
of several genes in more complex 3D models of bone formation
and for other tissues and disease focuses. Our study did not aim
to show difference in levels of osteogenesis between pBMP2-
GET and pBMP2-PLGA-GET transfection systems in vitro. Both
NPs are highly effective at transfecting hMSCs and initiating
osteogenesis, and now require extensive in vivo comparison, as
in our previous studies (Raftery et al., 2019).
We successfully encapsulated pDNA in PLGA NPs to take
advantage of the characteristics of PLGA; aiming to promote
pDNA protection and GET peptide complexation for an off-
the-shelf gene therapy product as a first-in-class technology.
Importantly using hard PLGA NPs for gene delivery has the
potential to be used in vivo to enhance local bone formation,
with or without biomaterial scaffold constructs. Examples
would include injection directly into defects or into soft tissue
surrounding it to induce osteogenesis. Other applications, such as
ex vivo transfection of MSCs in compromised inflammatory bone
defects and cell therapy, or directly in bone infections that would
require enhanced nuclease protection, could be exploited using
this system. Clearly our demonstrations of this system must move
in vivo; either demonstrating efficiency in regenerating critical-
size defects, or in subcutaneous ectopic bone formation assays,
which is now the focus of our work.
CONCLUSION
We have shown that employing FDA-approved material PLGA
NPs for gene delivery could be transformative by combining
the properties of nucleic acid protection, low toxicity and
translational advantages. When combining these with GET
peptide-mediated delivery the levels of transduction and
transfection are robust and potentially allow their use in many
biomedical areas. A versatile system that can be used to
deliver genes or genetic systems for specific diseases or trauma
treatment could have significant impact; especially when applying
gene augmentation and editing strategies to enhance future
regenerative medicine and cellular therapies.
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FIGURE S1 | Effect of serum albumin on PLGA-GET peptide interaction. Change
in zeta potential of PLGA-GET NPs upon their incubation in increasing
concentrations of FCS in SFM. The significant change in surface charge from
neutral to negative Indicates serum albumin electrostatic binding to GET on or
distant from the surface of PLGA NPs. The reduction in surface is charge is
proportional to the amount of serum in the media.
FIGURE S2 | Comparison of the physicochemical characteristics, intracellular
localization and transfection of pDNA-PR and pDNA-PLR NPs. (A) The effect of
lack of LK15 peptide in pDNA-PR NPs on their levels of transfection in
comparison to pDNA-PLR NPs. pDNA fluorescent labeling does not affect the
luciferase signal detected by luminometer; demonstrated by transfection in
unlabeled pDNA-PLR NPs positive control published in Dixon et al. (2016),
Corresponding 1 µg of pDNA. (B) pDNA condensation with PR and PLR
produced NPs of the same size range measured by Zetasizer excluding the effect
of variance in NP size on cellular internalization and transfection. (C) Both NPs
show intracellular localization detected by fluorescent microscopy imaging after
overnight transfection of NIH3T3 cells in GM. The pDNA-PR NPs show discrete
endosomal fluorescent NP accumulation in contrast to more diffuse pDNA-PLR
NPs in the cellular compartments. Scale bar 100 µm (D) Comparable intracellular
levels of NPs quantified by flow cytometry analysis shows no significant difference
between pDNA-PR and pDNA-PLR NP transduction levels.
FIGURE S3 | Characterization of pBMP2-FLR NPs. Characterization of the
physicochemical properties of pBMP2-FLR NPs indicates desirable (A) NP size
range and (B) surface charge for intracellular delivery. (C) Confirmation of NP
production and morphology by TEM imaging. Red arrows highlight individual NPs.
FIGURE S4 | Metabolic cell activity during osteogenic differentiation. Metabolic
activity of the transfected IHMSCs during the first 3 days of differentiation. The
cells retain at least 70% of viability during highest transfection levels
(post-transfection days 2 and 3).
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